SYNLAB Past Earnings Performance
Past criteria checks 2/6
SYNLAB's earnings have been declining at an average annual rate of -9%, while the Healthcare industry saw earnings growing at 11.1% annually. Revenues have been declining at an average rate of 11.5% per year. SYNLAB's return on equity is 3.8%, and it has net margins of 3.4%.
Key information
-9.0%
Earnings growth rate
-14.1%
EPS growth rate
| Healthcare Industry Growth | 13.4% |
| Revenue growth rate | -11.5% |
| Return on equity | 3.8% |
| Net Margin | 3.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How SYNLAB makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,615 | 89 | 1,159 | 0 |
| 31 Dec 23 | 2,635 | 92 | 1,163 | 0 |
| 30 Sep 23 | 2,691 | 129 | 1,191 | 0 |
| 30 Jun 23 | 2,772 | 69 | 1,197 | 0 |
| 31 Mar 23 | 2,892 | -37 | 1,213 | 0 |
| 31 Dec 22 | 3,251 | 151 | 1,231 | 0 |
| 30 Sep 22 | 3,542 | 345 | 1,264 | 0 |
| 30 Jun 22 | 3,693 | 404 | 1,265 | 0 |
| 31 Mar 22 | 3,888 | 653 | 1,247 | 0 |
| 31 Dec 21 | 3,765 | 608 | 1,209 | 0 |
| 30 Sep 21 | 3,703 | 591 | 1,155 | 0 |
| 30 Jun 21 | 3,561 | 385 | 1,119 | 0 |
| 31 Mar 21 | 3,080 | 225 | 1,026 | 0 |
| 31 Dec 20 | 2,621 | 36 | 962 | 0 |
| 31 Dec 19 | 1,906 | -122 | 817 | 0 |
| 31 Dec 18 | 1,808 | -51 | 776 | 0 |
| 31 Dec 17 | 1,817 | -166 | 870 | 0 |
| 31 Dec 16 | 1,570 | -230 | 689 | 0 |
| 31 Dec 15 | 845 | -169 | 401 | 0 |
Quality Earnings: SYAB has a large one-off gain of €84.4M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: SYAB became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SYAB has become profitable over the past 5 years, growing earnings by -9% per year.
Accelerating Growth: SYAB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SYAB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (15.5%).
Return on Equity
High ROE: SYAB's Return on Equity (3.8%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 02:21 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SYNLAB AG is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Blanka Porkolab | Barclays |
| Hassan Al-Wakeel | Barclays |
| Charlotte Friedrichs | Berenberg |